联合经支气管与经食管超声在正电子发射断层扫描淋巴结阴性肺癌中的诊断效度
单中心研究分析596例临床I至IVA期肺癌患者,均行PET-CT后接受联合超声(CUS,即EBUS联合EUS)及肺切除系统淋巴结清扫,以病理为参考标准。N2病变患病率8%,CUS诊断N2的敏感度14%、特异度98%、阴性预测值93%;对超过微小N2(N2b)的阴性预测值为98%。CUS诊断效能不受年龄、性别、BMI、肿瘤分级、肺叶位置或组织学类型显著影响(P>0.05)。
要点
- PET阴性淋巴结中N2患病率低(8%),CUS阴性预测值93%,可可靠排除显著N2病变。
- CUS对超过微小N2(N2b)的阴性预测值达98%,仅6/596例漏诊超过微小N2病变。
- CUS敏感度仅14%,阴性结果不能完全排除微小N2受累,37/43例CUS阴性者存在微小N2。
核心结论
- 在PET阴性纵隔淋巴结中N2患病率低,CUS对N2的阴性预测值为93%,对超过微小N2受累的阴性预测值为98%,诊断效能不受临床特征影响,可能减少侵入性操作需求。
研究设计与样本
- 单中心研究,分析596例临床I至IVA期肺癌患者病历,所有患者行PET-CT后接受CUS成像及肺切除系统淋巴结清扫,以淋巴结病理检查为参考标准。
诊断标准与关键数值
- CUS检测N2病变的敏感度14%、特异度98%、阴性预测值93%;对微小N2受累的阴性预测值为98%;N2患病率8%。
临床应用与阅片要点
- CUS对超过微小N2(N2b)的阴性预测值达98%,仅6/596例漏诊超过微小N2病变;敏感度与阴性预测值不受年龄、性别、BMI、肿瘤分级、肺叶位置或组织学类型显著影响(P>0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: The role of invasive mediastinal diagnostic methods in lung cancer with negative positron emission tomography (PET) remains unclear. This study aimed to determine the sensitivity and negative predictive value (NPV) of combined endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS), referred to as combined ultrasound (CUS), for diagnosing N2 disease in this group of patients.
MATERIALS AND METHODS: single-centre study analysing medical records of clinical stage I to IVA lung cancer patients was conducted. All patients underwent positron emission tomography computed tomography (PET-CT), followed by CUS imaging and lung resection with systematic lymph node dissection. Pathological examination of lymph nodes was the reference standard.
RESULTS: Data from 596 patients were analysed. The prevalence of N2 disease was 8%. The sensitivity, specificity, and the NPV of CUS in detecting N2 disease were 14%, 98%, and 93%, respectively. Sensitivity and NPV were not significantly associated with age, sex, body mass index (BMI), tumour grade, lobar location, or histological type (P > 0.05). Minimal N2 disease was found in 37 of 43 patients with negative CUS results; only 6 of 596 patients had more than minimal (N2b) disease missed by CUS. The NPV for minimal N2 involvement was 98%.
CONCLUSION: In PET-negative mediastinal lymph nodes, N2 disease prevalence is low. CUS has an NPV of 93% for N2 disease and 98% for more than minimal N2 involvement. The diagnostic yield of CUS is unaffected by clinical characteristics, making it a reliable method for ruling out significant N2 disease in PET-negative patients and potentially reducing the need for more invasive procedures.
引用
- Gambuś K, Kużdżał B, Moszczyński K, et al. Diagnostic validity of combined transbronchial and transoesophageal ultrasound in positron emission tomography node-negative lung cancer. Clin Radiol. 2025. PMID: 40037138. doi:10.1016/j.crad.2025.106843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。